Results 61 to 70 of about 2,202,582 (329)

Anticancer Activity of Paclitaxel-Loaded Mesoporous Silica Nanoparticles in B16F10 Melanoma-Bearing Mice

Pharmaceutics
Background/Objectives: Paclitaxel (PTX) faces clinical limitations in melanoma treatment due to poor solubility, P-glycoprotein (P-gp)-mediated efflux, and systemic toxicity.
Jihoon Lee, Jung Mo Kim, Yeon-Ju Baek, Hyojeung Kang, Min-Koo Choi, Im-Sook Song   +5 more
doaj   +1 more source

Evaluation of linear classifiers on articles containing pharmacokinetic evidence of drug-drug interactions

, 2012
Background. Drug-drug interaction (DDI) is a major cause of morbidity and mortality. [...] Biomedical literature mining can aid DDI research by extracting relevant DDI signals from either the published literature or large clinical databases.
Kolchinsky, Artemy, Li, Lang, Lourenço, Anália, Rocha, Luis M.   +3 more
core   +1 more source

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir [PDF]

, 2021
Felix Stader, Manuel Battegay, Catia Marzolini   +2 more
openalex   +1 more source

By dawn or dusk—how circadian timing rewrites bacterial infection outcomes

FEBS Letters, EarlyView.
The circadian clock shapes immune function, yet its influence on infection outcomes is only beginning to be understood. This review highlights how circadian timing alters host responses to the bacterial pathogens Salmonella enterica, Listeria monocytogenes, and Streptococcus pneumoniae revealing that the effectiveness of immune defense depends not only
Devons Mo, Catherine S. Palmer, Jacqueline M. Kimmey   +2 more
wiley   +1 more source

An evaluation of adverse drug reactions and outcomes attributed to kratom in the US Food and Drug Administration Adverse Event Reporting System from January 2004 through September 2021

Clinical and Translational Science, 2023
Kratom is a widely used Asian botanical that has gained popularity in the United States due to a perception that it can treat pain, anxiety, and opioid withdrawal symptoms. The American Kratom Association estimates 10–16 million people use kratom. Kratom‐
Xiaotong Li, Patrick Ndungu, Sanya B. Taneja, Maryann R. Chapin, Susan B. Egbert, Krishi Akenapalli, Mary F. Paine, Sandra L. Kane‐Gill, Richard D. Boyce   +8 more
doaj   +1 more source

The relationship of drug reimbursement with the price and the quality of pharmaceutical innovations [PDF]

, 2005
This paper studies the strategic interaction between pharmaceutical firms' pricing decisions and government agencies' reimbursement decisions which discriminate between patients by giving reimbursement rights to patients for whom the drug is most ...
García-Alonso, M. D. C., Mariñoso, B. G.   +1 more
core  

Outcome-based pricing for new pharmaceuticals via rebates [PDF]

, 2020
The price of new brand-name prescription drugs has been rising fast in the United States. For example, the Amgen cholesterol drug Repatha had an initial list price of $14,523 per year.
Adida, E
core  

Predicting drug–drug interactions through drug structural similarities and interaction networks incorporating pharmacokinetics and pharmacodynamics knowledge [PDF]

, 2017
Additional file 1. Table S1. Average structural similarity scores for the DDI/non–DDI pairs in the network of each De. Table S2-1. Top 10 predicted drugs with DDIs for warfarin. Table S2-2. Top 10 predicted drugs with DDIs for simvastatin. Table S3. Four-
Ming Hao, Stephen H. Bryant, Takako Takeda, Tiejun Cheng, Yanli Wang   +4 more
core   +2 more sources

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

FEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes, Guilherme M. Azevedo, Amanda P. Barcellos, Diana Bahia   +3 more
wiley   +1 more source

Structural insights into lacto‐N‐biose I recognition by a family 32 carbohydrate‐binding module from Bifidobacterium bifidum

FEBS Letters, EarlyView.
Bifidobacterium bifidum establishes symbiosis with infants by metabolizing lacto‐N‐biose I (LNB) from human milk oligosaccharides (HMOs). The extracellular multidomain enzyme LnbB drives this process, releasing LNB via its catalytic glycoside hydrolase family 20 (GH20) lacto‐N‐biosidase domain.
Xinzhe Zhang, Naoki Sunagawa, Toma Kashima, Kiyohiko Igarashi, Akimasa Miyanaga, Shinya Fushinobu   +5 more
wiley   +1 more source